Pharmaceutical stocks decline after RFK Jr. nominated as U.S. Health Secretary

Stocks of major pharmaceutical companies have fallen following the nomination of Robert F. Kennedy Jr. as the next U.S. Health Secretary. Kennedy Jr. is known for his strong opposition to Big Pharma and vaccine skepticism. On Wednesday, shares of Moderna dropped 5.62%, while Pfizer fell 2.62%. Other companies, including Novavax and BioNTech, also experienced significant declines. The market continued to react negatively on Thursday. Kennedy Jr. has expressed intentions to reform health agencies and has criticized the pharmaceutical industry. His nomination has raised concerns about potential changes in health policy and regulation.